Eupraxia Pharmaceuticals (EPRX) Current Assets (2022 - 2026)
Eupraxia Pharmaceuticals (EPRX) posted quarterly Current Assets of $142.1 million for Q1 2026, up 396.83% year-over-year from $28.6 million in Q1 2025, and up 67.01% quarter-over-quarter from $85.1 million in Q4 2025.
Eupraxia Pharmaceuticals (EPRX) Current Assets (2022 - 2026) Analysis & Trends
Eupraxia Pharmaceuticals (EPRX) has reported Current Assets for 5 consecutive years, with $142.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Current Assets rose 396.83% year-over-year to $142.1 million; the TTM figure through Mar 2026 stood at $142.1 million (up 396.83% YoY), while the FY2025 annual figure was $85.1 million, up 147.12% from the prior year.
- Current Assets rose to $142.1 million in Q1 2026 per EPRX's latest filing, from $85.1 million in the prior quarter.
- Across five years, Current Assets topped out at $142.1 million in Q1 2026 and bottomed at $9.9 million in Q3 2024.
- Historically, Current Assets has averaged $46.7 million across 5 years, with a median of $28.6 million in 2025.
- On a YoY basis, Current Assets climbed as much as 824.17% in 2025 and fell as far as 21.01% in 2025.
- Eupraxia Pharmaceuticals' Current Assets stood at $18.6 million in 2022, then rose by 6.53% to $19.8 million in 2023, then soared by 73.9% to $34.4 million in 2024, then soared by 147.12% to $85.1 million in 2025, then soared by 67.01% to $142.1 million in 2026.
- Business Quant data shows EPRX's Current Assets at $142.1 million in Q1 2026, $85.1 million in Q4 2025, and $91.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 8.07 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.03 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 7.22 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 11.83 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 1.76 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.62 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.63 Bn |
| 10 | Eupraxia Pharmaceuticals | 381.11 Mn | 379.51 Mn | - | 142.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 142.13 Mn |
| Dec 31, 2025 | 85.10 Mn |
| Sep 30, 2025 | 91.40 Mn |
| Jun 30, 2025 | 22.83 Mn |
| Mar 31, 2025 | 28.61 Mn |
| Dec 31, 2024 | 34.44 Mn |
| Sep 30, 2024 | 9.89 Mn |
| Jun 30, 2024 | 24.53 Mn |
| Mar 31, 2024 | 36.22 Mn |
| Dec 31, 2023 | 19.80 Mn |
| Dec 31, 2022 | 18.59 Mn |